Nutrients · 2022 · 10 citations · 23 references
PharmacyNutritional SciencesPharmacologyClinical NutritionClinical PharmacologyHuman NutritionCardiovascular DiseaseDyslipidemia ManagementDyslipidemia PharmacotherapyLipid ManagementLipid-lowering TherapyVitamin K TherapyCholesterol-lowering EffectsDouble-blind TrialsLipid Profile AnalysisLipid Profile ChangesLipid Profile EffectsLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionPlacebo-controlled Efficacy Assessment
Background: Nutraceutical combinations (NCs) against hypercholesterolemia are increasing in the marketplace. However, the availability of NCs without monacolin K is scarce even though the statin-intolerant population needs it. Methods: This study is a parallel-group, randomized, placebo-controlled, double-blind trial. We evaluated the effects of the NC containing phytosterols, bergamot, olive fruits, and vitamin K2 on lipid profile and inflammatory biomarkers in 118 subjects (mean age ± SD, 57.9 ± 8.8 years; 49 men and 69 women) with hypercholesterolemia (mean total cholesterol ± SD, 227.4 ± 20.8 mg/dL) without clinical history of cardiovascular diseases. At baseline and 6 and 12 weeks of treatment, we evaluated lipid profile (total, LDL and HDL cholesterol, and triglycerides), safety (liver, kidney, and muscle parameters), and inflammatory biomarkers such as hs-CRP, leukocytes, interleukin-32, and interleukin-38 and inflammatory-microRNAs (miRs) miR-21, miR-126, and miR-146a. Results: Compared to the placebo, at 6 and 12 weeks, NC did not significantly reduce total cholesterol (p = 0.083), LDL cholesterol (p = 0.150), and triglycerides (p = 0.822). No changes were found in hs-CRP (p = 0.179), interleukin-32 (p = 0.587), interleukin-38 (p = 0.930), miR-21 (p = 0.275), miR-126 (p = 0.718), miR-146a (p = 0.206), myoglobin (p = 0.164), and creatine kinase (p = 0.376). Among the two reported, only one adverse event was probably related to the nutraceutical treatment. Conclusions: The evaluated nutraceutical combination did not change serum lipid profile and inflammatory parameters, at least not with the daily dose applied in the present study.
23
Ömer Toprak, Hüseyin Kurt, Yasin Sarı et al. · Kidney & Blood Pressure Research · 2017 · 29.7K citations · Full text
Medicine, Endocrinology, Nutrition +17
Evaluation Expert Panel on Detection · JAMA · 2001 · 26K citations
Medicine, Cardiology, Otolaryngology +10
Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall et al. · European Heart Journal · 2016 · 6.5K citations · Full text
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano, Ian Graham, Guy De Backer et al. · European Heart Journal · 2016 · 3.2K citations · Full text